First Trust Hedged BuyWrite Income ETF (FTLB) At $22.48 Forms Bottom; Shorts at Capricor Therapeutics (CAPR) Raised By 2.87%

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Capricor Therapeutics Inc (NASDAQ:CAPR) had an increase of 2.87% in short interest. CAPR’s SI was 1.56M shares in July as released by FINRA. Its up 2.87% from 1.52M shares previously. With 352,200 avg volume, 4 days are for Capricor Therapeutics Inc (NASDAQ:CAPR)’s short sellers to cover CAPR’s short positions. The SI to Capricor Therapeutics Inc’s float is 11.64%. It closed at $1.34 lastly. It is down 61.45% since July 1, 2017 and is uptrending. It has outperformed by 48.88% the S&P500. Some Historical CAPR News: 08/03/2018 Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14; 21/04/2018 – DJ Capricor Therapeutics Inc, Inst Holders, 1Q 2018 (CAPR); 19/04/2018 – CAPR: PRECLINICAL CAP-1002 STUDY SHOWED EXERCISE CAPACITY BOOST; 30/04/2018 – CAPRICOR:HOPE-2 CLINICAL TRIAL OF CAP-1002 FOR DUCHENNE STARTED; 12/04/2018 – Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day; 30/04/2018 – Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy; 14/03/2018 – Capricor Therapeutics 4Q Net $12.3M; 10/05/2018 – Capricor Therapeutics 1Q Loss/Shr 14c; 14/03/2018 – Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update; 14/03/2018 – Capricor Therapeutics 4Q EPS 42c

First Trust Hedged BuyWrite Income ETF (FTLB) formed multiple bottom with $20.91 target or 7.00% below today’s $22.48 share price. First Trust Hedged BuyWrite Income ETF (FTLB) has $8.87 million valuation. The ETF increased 0.99% or $0.22 during the last trading session, reaching $22.48. About 7,690 shares traded or 58.17% up from the average. First Trust Hedged BuyWrite Income ETF (NASDAQ:FTLB) has risen 4.95% since July 1, 2017 and is uptrending. It has underperformed by 7.62% the S&P500.

More recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: which released: “Capricor Therapeutics to Present at PPMD Annual Conference” on June 28, 2018. Also published the news titled: “Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis …” on June 13, 2018.‘s news article titled: “Sarepta set to pop on encouraging data on DMD gene therapy” with publication date: June 19, 2018 was also an interesting one.

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Friday, May 11 report. On Friday, January 26 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, March 29.

Investors sentiment decreased to 0.44 in 2018 Q1. Its down 3.89, from 4.33 in 2017Q4. It fall, as 4 investors sold Capricor Therapeutics, Inc. shares while 5 reduced holdings. 3 funds opened positions while 1 raised stakes. 1.04 million shares or 76.59% less from 4.44 million shares in 2017Q4 were reported. Acadian Asset Mngmt Limited Liability Corp accumulated 60,753 shares. California-based Apriem Advisors has invested 0.02% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Comml Bank Of America Corp De reported 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR). New York-based Virtu Fincl Ltd Liability Corporation has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Geode Mgmt Limited Liability reported 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Deutsche Savings Bank Ag reported 600 shares or 0% of all its holdings. Vanguard Gp has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Cordasco Net invested in 0% or 3,100 shares. Northern has 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR). State Bank Of Mellon stated it has 26,762 shares. Royal Commercial Bank Of Canada owns 232 shares or 0% of their US portfolio. Blackrock invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Perceptive Limited Liability Company invested in 0% or 4,000 shares. Fincl Architects invested in 2,000 shares or 0% of the stock. Morgan Stanley holds 2 shares.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company has market cap of $39.01 million. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 15.76 P/E ratio.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart